Our Partners
GMDx Genomics
Deaminase science, providing a foundation
beneath precision oncology.
Endogenous deaminase enzymes leave characteristic signatures in the genome. GMDx reads them in their codon context and attributes each mutation to its biological source. One AI-enabled platform, a globally protected IP estate, applied across diagnostics and drug development.
45
active patent assets across four families
11 + EP
national jurisdictions plus European coverage
2012
foundation priority date
0.86
AUC, ahead of TMB and PD-L1
THE GAP GMDX CLOSES
Today's biomarkers tell you who might respond. The harder question is who is unlikely to benefit.
Checkpoint inhibitors cost USD 100,000–200,000+ per patient per year and carry serious side effects, yet the biomarkers in routine use identify responders with only 60–66% accuracy. GMDx adds the mechanistic layer that existing sequencing and AI genomics models lack.
THE GAP GMDX CLOSES
Condon-context causality
Proprietary Targeted Somatic Mutation methods identify the deaminase source of each mutation in its sequence context.
THE GAP GMDX CLOSES
The Immune Fitness Profile
An AI-enabled pipeline extracting 41,162 genomic metrics per profile, scored against a 20,000+ patient reference database.
THE GAP GMDX CLOSES
A foundational IP estate
Forty-five active assets across four families, with a foundation priority that predates known third-party work in the field.
Research Collaborators
INDUSTRY PARTNERS
